GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Price-to-Tangible-Book

INKT (MiNK Therapeutics) Price-to-Tangible-Book : (As of Sep. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Price-to-Tangible-Book?

As of today (2024-09-20), MiNK Therapeutics's share price is $0.7538. MiNK Therapeutics's Tangible Book per Share of Jun. 2024 for the quarter that ended in Jun. 2024 was $-0.42. Hence, MiNK Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for MiNK Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 5 years, MiNK Therapeutics's highest Price to Tangible Book Ratio was 10.55. The lowest was 3.46. And the median was 5.32.

INKT's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.77
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, MiNK Therapeutics's share price is $0.7538. MiNK Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2024 was $-0.42. Hence, MiNK Therapeutics's P/B Ratio of today is .


MiNK Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for MiNK Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Price-to-Tangible-Book Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 6.28 - -

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MiNK Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, MiNK Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Price-to-Tangible-Book falls into.



MiNK Therapeutics Price-to-Tangible-Book Calculation

MiNK Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2024 )
=0.7538/-0.42
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


MiNK Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010